1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Celsus Therapeutics Plc - Product Pipeline Review - 2015

Celsus Therapeutics Plc - Product Pipeline Review - 2015

  • August 2015
  • -
  • Global Markets Direct
  • -
  • 24 pages

Celsus Therapeutics Plc - Product Pipeline Review - 2015

Summary

Global Markets Direct’s, ‘Celsus Therapeutics Plc - Product Pipeline Review - 2015’, provides an overview of the Celsus Therapeutics Plc’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Celsus Therapeutics Plc’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Celsus Therapeutics Plc including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Celsus Therapeutics Plc’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Celsus Therapeutics Plc’s pipeline products

Reasons to buy

- Evaluate Celsus Therapeutics Plc’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Celsus Therapeutics Plc in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Celsus Therapeutics Plc’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Celsus Therapeutics Plc and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Celsus Therapeutics Plc
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Celsus Therapeutics Plc and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Table Of Contents

Celsus Therapeutics Plc - Product Pipeline Review - 2015
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Celsus Therapeutics Plc Snapshot 5
Celsus Therapeutics Plc Overview 5
Key Information 5
Key Facts 5
Celsus Therapeutics Plc - Research and Development Overview 6
Key Therapeutic Areas 6
Celsus Therapeutics Plc - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Celsus Therapeutics Plc - Pipeline Products Glance 10
Celsus Therapeutics Plc - Early Stage Pipeline Products 10
Preclinical Products/Combination Treatment Modalities 10
Celsus Therapeutics Plc - Drug Profiles 11
CFX-1 11
Product Description 11
Mechanism of Action 11
RandD Progress 11
MRX-5 12
Product Description 12
Mechanism of Action 12
RandD Progress 12
OAX-1 13
Product Description 13
Mechanism of Action 13
RandD Progress 13
OPX-1 14
Product Description 14
Mechanism of Action 14
RandD Progress 14
Celsus Therapeutics Plc - Pipeline Analysis 15
Celsus Therapeutics Plc - Pipeline Products by Target 15
Celsus Therapeutics Plc - Pipeline Products by Route of Administration 16
Celsus Therapeutics Plc - Pipeline Products by Molecule Type 17
Celsus Therapeutics Plc - Pipeline Products by Mechanism of Action 18
Celsus Therapeutics Plc - Recent Pipeline Updates 19
Celsus Therapeutics Plc - Dormant Projects 21
Celsus Therapeutics Plc - Locations And Subsidiaries 22
Head Office 22
Other Locations and Subsidiaries 22
Appendix 23
Methodology 23
Coverage 23
Secondary Research 23
Primary Research 23
Expert Panel Validation 23
Contact Us 23
Disclaimer 24

List of Tables
Celsus Therapeutics Plc, Key Information 5
Celsus Therapeutics Plc, Key Facts 5
Celsus Therapeutics Plc - Pipeline by Indication, 2015 7
Celsus Therapeutics Plc - Pipeline by Stage of Development, 2015 8
Celsus Therapeutics Plc - Monotherapy Products in Pipeline, 2015 9
Celsus Therapeutics Plc - Preclinical, 2015 10
Celsus Therapeutics Plc - Pipeline by Target, 2015 15
Celsus Therapeutics Plc - Pipeline by Route of Administration, 2015 16
Celsus Therapeutics Plc - Pipeline by Molecule Type, 2015 17
Celsus Therapeutics Plc - Pipeline Products by Mechanism of Action, 2015 18
Celsus Therapeutics Plc - Recent Pipeline Updates, 2015 19
Celsus Therapeutics Plc - Dormant Developmental Projects,2015 21
Celsus Therapeutics Plc, Other Locations 22
Celsus Therapeutics Plc, Subsidiaries 22

List of Figures
Celsus Therapeutics Plc - Pipeline by Top 10 Indication, 2015 7
Celsus Therapeutics Plc - Pipeline by Top 10 Target, 2015 15
Celsus Therapeutics Plc - Pipeline by Top 10 Route of Administration, 2015 16
Celsus Therapeutics Plc - Pipeline Products by Top 10 Mechanism of Action, 2015 18

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Tyrosine Protein Kinase Me ...

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016’, provides in depth analysis ...

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Iduronate 2 Sulfatase (Alpha L Iduronate ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.